Cancer Care Ontario | Action Cancer Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

7 Results

Guidelines and Advice

Radionuclide Therapy for Neuroendocrine Malignancies

Status: Current
ID: 12-13

Dec 1969

Guidelines and Advice

Radiopharmaceuticals in the Palliation of Painful Bone Metastases

Status: Archived
ID: 14-1

Jan 2015

Guidelines and Advice

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

Status: Current
ID: GL-C50-01

Jan 2011

Guidelines and Advice

Recommendations for the Delivery of Psychosocial Oncology Services in Ontario

Status: Current

Dec 1969

Guidelines and Advice

Oncology Caregiver Support Framework

Status: Current
ID: N/A
Version: N/A

Oct 2019

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Guidelines and Advice

Organizational Guidance for the Care of Patients with Central Nervous System Tumours in Ontario: Consensus Recommendations

Status: Current
ID: GL 9-11

Oct 2024